Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 13/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | METAP2 | P50579 | 1/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | PRKCG | P05129 | 1/20 | 0.50 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14336639 | 0.88 | KCNH2 (0.62) | SCN10AKCNH2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL15746239 | 0.86 | SCN10A (0.60) | SCN10AKCNH2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL846855 | 0.85 | SCN10A (0.58) | SCN10AKCNH2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL19887995 | 0.84 | SCN10A (0.57) | SCN10AKCNH2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL15746214 | 0.83 | SCN10A (0.56) | SCN10AKCNH2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL3269719 | 0.81 | ALDH1A1 (0.58) | SCN10AKCNH2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL805057 | 0.81 | GAA (0.68) | SCN10AKCNH2ALDH1A1METAP2PLK4 | |
| SCHEMBL9058427 | 0.81 | HDAC6 (0.62) | SCN10AKCNH2ALDH1A1SMN1; SMN2METAP2 | |
| SCHEMBL22326618 | 0.81 | SCN10A (0.55) | SCN10AKCNH2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17085004 | 0.81 | HPGD (0.61) | SCN10AKCNH2ALDH1A1SMN1; SMN2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20220021012-A1 | ELECTROLYTE MEMBRANE FOR MEMBRANE-ELECTRODE ASSEMBLY COMPRISING FILLER IMPROVING ION CONDUCTIVITY | KIA MOTORS CORPORATION (KR) | 2022-01-20 | — | — | US | disclosed |
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| US-8143414-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-7626030-B2 | Compounds and methods of use | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | SCN10A 4501/4885KCNH2 4401/4885ALDH1A1 252/4885 |
| US-20120115918-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885KCNH2 4523/4885ALDH1A1 2858/4885 |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | SCN10A 1189/4885KCNH2 2077/4885ALDH1A1 1393/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885KCNH2 4523/4885ALDH1A1 2858/4885 |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | SCN10A 1189/4885KCNH2 2077/4885ALDH1A1 1393/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | SCN10A 3849/4885KCNH2 4818/4885ALDH1A1 2808/4885 |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | SCN10A 3860/4885KCNH2 4406/4885ALDH1A1 4501/4885 |
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | SCN10A 3496/4885KCNH2 4410/4885ALDH1A1 4171/4885 |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | SCN10A 4182/4885KCNH2 4811/4885ALDH1A1 2177/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | SCN10A 1246/4885KCNH2 296/4885ALDH1A1 800/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SCN10A 4642/4885KCNH2 4228/4885ALDH1A1 3957/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | SCN10A 1232/4885KCNH2 2846/4885ALDH1A1 1643/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | SCN10A 1189/4885KCNH2 2077/4885ALDH1A1 1393/4885 |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | SCN10A 1189/4885KCNH2 2077/4885ALDH1A1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.